MUTUAL NON-DISCLOSURE AGREEMENTNon-Disclosure Agreement • June 17th, 2022 • Turning Point Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Mutual Non-Disclosure Agreement (“Agreement”) is made effective as of March 6, 2022 (the “Effective Date”), by and between Turning Point Therapeutics, Inc., a Delaware corporation (“Turning Point”), and Bristol-Myers Squibb Company, a Delaware corporation (“Company”), for the purpose of assuring the protection and preservation of the confidential and/or proprietary nature of information to be made available by each party to the other in connection with the parties’ evaluation of a potential business relationship between the parties and/or their Affiliates (the “Authorized Purpose”). The parties hereby agree as follows:
